Drugs & Aging

, Volume 16, Issue 5, pp 365–379 | Cite as

Role of Dopamine in Learning and Memory

Implications for the Treatment of Cognitive Dysfunction in Patients With Parkinson’s Disease
  • Jaime Kulisevsky
Review Article


Along with dementia, Parkinson’s disease (PD) is associated with subtle but widespread cognitive impairment even in the absence of clinically apparent cognitive decline. Many of the deficits are reminiscent of those observed in patients with lesions of the prefrontal cortex, that is, failure in executive function that involves skills required for anticipation, planning, initiation and monitoring of goal-directed behaviours. This paper reviews the dopaminergic brain circuitry, and preclinical and clinical evidence supporting the regulation of prefrontal cortex activity by dopamine, and the role of dopamine in cognitive impairment in patients with PD. It addresses the need to integrate these facts and the findings of positive, neutral or detrimental frontal cognitive response to dopaminergic drugs in PD which should be viewed mainly in the context of methodological differences for subject selection.

The cognitive effect of levodopa does not much depend on a neuropsychological specificity of the drug, the years of evolution of the disease or the severity of the motor signs. Instead, it may be a function of the level of dopamine depletion in different parts of the basal ganglia and prefrontal cortex. Consequently, dopaminergic agents may enhance cognitive functions in some patients and impair them in others. De novo patients tend to improve during the first year of treatment; stable responders to oral levodopa tend to show no changes; and wearing-off responders tend to deteriorate with acute levodopa challenge. Enhancement and impairment of cognitive function with dopaminergic treatment is incomplete and task-specific, suggesting the need to integrate the above dopamine facts with other neurotransmitter systems findings in PD. Meanwhile, such cognitive dissociation can be useful in refining the definition of the cognitive deficit in PD patients without dementia and emphasising the need to develop new and specific strategies for treatment.


Levodopa Bromocriptine Lewy Body Pergolide Wisconsin Card Sort Test 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



The author wishes to thank Asunción Àvila, Manel Barbanoj, Carmen García-Sánchez, Berta Pascual-Sedano, Alexandre Gironell and Dolores López-Villegas for their assistance in performing some of the studies described in this review. Marcelo L. Berthier is also acknowledged for his many helpful suggestions. This work was partially supported by a grant from Fundació la Maratò de TV3 (Exp. 025/97).


  1. 1.
    Marsden CD. Parkinson’s disease. J Neurol Neurosurg Psychiatry 1994; 57: 672–81PubMedCrossRefGoogle Scholar
  2. 2.
    Brown RG, Marsden CD. How common is dementia in Parkinson’s disease? Lancet 1984; I: 1262–5CrossRefGoogle Scholar
  3. 3.
    Mayeux R, Stern Y, Rosenstein R, et al. An estimate of the prevalence of dementia in idiopathic Parkinson’s disease. Arch Neurol 1988; 45: 260–2PubMedCrossRefGoogle Scholar
  4. 4.
    Mayeux R, Denaro J, Hemenglido N, et al. A population-based investigation of Parkinson’s disease with and without dementia. Arch Neurol 1992; 49: 492–7PubMedCrossRefGoogle Scholar
  5. 5.
    Friedman A, Barciczikowska M. Dementia in Parkinson’s disease. Dementia 1994; 5: 12–6PubMedGoogle Scholar
  6. 6.
    Tison F, Dartigues JF, Auriacombe S, et al. Dementia in Parkinson’s disease: a population-based study in ambulatory and institutionalized individuals. Neurology 1995; 45: 705–8PubMedCrossRefGoogle Scholar
  7. 7.
    Huberman M, Moscovitch M, Freedman M. Comparisons of patients with Alzheimer’s and Parkinson’s disease on different explicit and implicit tests of memory. Neuropsychiatry Neuropsychol Behav Neurol 1994; 7: 185–93Google Scholar
  8. 8.
    McFadden L, Mohr E, Sampson M, et al. A profile analysis of demented and nondemented Parkinson’s disease patients. Adv Neurol 1996; 69: 339–41PubMedGoogle Scholar
  9. 9.
    Levin BE, Llabre MM, Weiner WJ. Cognitive impairments associated with early Parkinson’s disease. Neurology 1989; 39: 557–61PubMedCrossRefGoogle Scholar
  10. 10.
    Cooper JA, Sagar HJ, Jordan N, et al. Cognitive impairment in early, untreated, Parkinson’s disease and its relationship to motor disability. Brain 1991; 114: 2095–122PubMedCrossRefGoogle Scholar
  11. 11.
    Goldman WP, Baty JD, Buckles VD, et al. Cognitive and motor functioning in Parkinson’s disease. Arch Neurol 1998; 55: 674–80PubMedCrossRefGoogle Scholar
  12. 12.
    Youngjohn JR, Beck J, Jogerst G, et al. Neuropsychological impairment, depression, and Parkinson’s disease. Neuropsychology 1992; 6: 149–58CrossRefGoogle Scholar
  13. 13.
    Ross HF, Hughes TA, Boyd JL, et al. The evolution and profile of dementia in Parkinson’s disease. Adv Neurol 1996; 69: 343–7PubMedGoogle Scholar
  14. 14.
    Kuzis G, Sabe L, Tiberti C, et al. Cognitive function in major depression and Parkinson’s disease. Arch Neurol 1997; 54: 982–6PubMedCrossRefGoogle Scholar
  15. 15.
    Churchyard A, Lees AJ. The relationship between dementia and direct involvement of the hippocampus and amygdala in Parkinson’s disease. Neurology 1992; 49: 1570–6CrossRefGoogle Scholar
  16. 16.
    Jellinger KA. Morphological substrates of dementia in parkinsonism: a critical update. J Neural Transm 1997; Suppl. 51: 57–82Google Scholar
  17. 17.
    Hely MA, Reid WGJ, Halliday GM, et al. Diffuse Lewy body disease: clinical features in nine cases without coexistent Alzheimer’s disease. J Neurol Neurosurg Psychiatry 1996; 60: 531–8PubMedCrossRefGoogle Scholar
  18. 18.
    McKeith IG, Galasko D, Kosaka K, et al. Consensus guideline for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB international workshop. Neurology 1996; 47: 1113–24PubMedCrossRefGoogle Scholar
  19. 19.
    Kosaka K, Yoshimura M, Ikeda K, et al. Diffuse type of Lewy body disease: progressive dementia with abundant cortical Lewy bodies and senile changes of various degrees: a new disease. Clin Neuropathol 1984; 3: 185–92PubMedGoogle Scholar
  20. 20.
    Hansen LA, Salmon D, Galasko D, et al. The Lewy body variant of Alzheimer’s disease. Neurology 1990; 40: 1–8PubMedCrossRefGoogle Scholar
  21. 21.
    Perry RH, Irving D, Blessed G, et al. Clinically and neuro-pathologically distinct form of dementia in the elderly [letter]. Lancet 1989; I: 1166Google Scholar
  22. 22.
    Lees AJ, Smith E. Cognitive deficits in the early stages of Parkinson’s disease. Brain 1983; 106: 257–70PubMedCrossRefGoogle Scholar
  23. 23.
    Huber SJ, Schulman HG, Paulson GW, et al. Fluctuations in plasma dopamine level impair memory in Parkinson’s disease. Neurology 1987; 37: 1371–5PubMedCrossRefGoogle Scholar
  24. 24.
    Kulisevsky J, Avila A, Barbanoj M, et al. Acute effects of levo-dopa on neuropsychological performance in stable and fluctuating Parkinson’s disease patients at different levodopa plasma levels. Brain 1996; 119: 2121–32PubMedCrossRefGoogle Scholar
  25. 25.
    Warburton JW. Memory disturbance and the Parkinson syndrome. Br J Med Psychol 1967; 40: 169–71PubMedCrossRefGoogle Scholar
  26. 26.
    Wilson RS, Kaszniak AW, Klawans HL, et al. High speed memory scanning in parkinsonism. Cortex 1980; 16: 67–72PubMedGoogle Scholar
  27. 27.
    Boller F, Passafiume D, Keefe NC, et al. Visuospatial impairment in Parkinson’s disease: role of perceptual and motor factors. Arch Neurol 1984; 41: 485–90PubMedCrossRefGoogle Scholar
  28. 28.
    Brown RG, Marsden CD, Quinn N, et al. Alterations in cognitive performance and affect-arousal state during fluctuations in motor function in Parkinson’s disease. J Neurol Neurosurg Psychiatry 1984; 47: 454–65PubMedCrossRefGoogle Scholar
  29. 29.
    Downes JJ, Roberts AC, Sahakian BJ, et al. Impaired extra-dimensional shift performance in medicated and unmedicated Parkinson’s disease: evidence for a specific attentional dysfunction. Neuropsychologia 1989; 27: 1329–43PubMedCrossRefGoogle Scholar
  30. 30.
    Bowen FP, Kamienny MA, Burns MM, et al. Parkinsonism: effects of L-dopa on concept formation. Neurology 1975; 25: 701–4PubMedCrossRefGoogle Scholar
  31. 31.
    Dubois B, Pillon B, Sternic C, et al. Age-induced cognitive disturbances in Parkinson’s disease. Neurology 1990; 40: 38–41PubMedCrossRefGoogle Scholar
  32. 32.
    Hietanen M, Teravainen H. The effect of age of disease onset on neuropsychological performance in Parkinson’s disease. J Neurol Neurosurg Psychiatry 1988; 51: 244–9PubMedCrossRefGoogle Scholar
  33. 33.
    Tsai CH, Lu CS, Hua MS, et al. Cognitive dysfunction in early onset parkinsonism. Acta Neurol Scand 1994; 89: 9–14PubMedCrossRefGoogle Scholar
  34. 34.
    Wermuth L, Knudsen L, Boldsen J. A study of cognitive functions in young Parkinsonian patients. Acta Neurol Scand 1996; 93: 21–4PubMedCrossRefGoogle Scholar
  35. 35.
    Starkstein SE, Preziosi TJ, Berthier ML, et al. Depression and cognitive impairment in Parkinson’s disease. Brain 1989; 112: 1141–53PubMedCrossRefGoogle Scholar
  36. 36.
    Cummings JL. Depression and Parkinson’s disease: a review. Am J Psychiatry 1992; 149: 443–54PubMedGoogle Scholar
  37. 37.
    Tröster AI, Stalp LD, Paolo AM, et al. Neuropsychological impairment in Parkinson’s disease with and without depression. Arch Neurol 1995; 52: 1164–9PubMedCrossRefGoogle Scholar
  38. 38.
    Jacobs DM, Marder K, Cote LJ, et al. Neuropsychological characteristics of preclinical dementia in Parkinson’s disease. Neurology 1995; 45: 1691–6PubMedCrossRefGoogle Scholar
  39. 39.
    Mahieux F, Fénelon G, Flahault A, et al. Neuropsychological prediction of dementia in Parkinson’s disease. J Neurol Neurosurg Psychiatry 1998; 64: 178–83PubMedCrossRefGoogle Scholar
  40. 40.
    Graham JM, Sagar HJ. A data-driven approach to the study of heterogeneity in idiopathic Parkinson’s disease: identification of three distinct subtypes. Mov Disord 1999; 14: 10–20PubMedCrossRefGoogle Scholar
  41. 41.
    Taylor AE, Saint-Cyr JA, Lang AE. Parkinson’s disease: cognitive changes in relation to treatment response. Brain 1987; 110: 35–51PubMedCrossRefGoogle Scholar
  42. 42.
    Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson’s disease. Arch Neurol 1999; 56: 33–9PubMedCrossRefGoogle Scholar
  43. 43.
    Brown RG, Marsden CD. Cognitive function in Parkinson’s disease: from description to theory. Trends Neurosci 1990; 13: 21–9PubMedCrossRefGoogle Scholar
  44. 44.
    Pillon B, Dubois B, Lhermitte F, et al. Heterogeneity of cognitive impairment in progressive supranuclear palsy, Parkinson’s disease, and Alzheimer’s disease. Neurology 1986; 36: 1179–85PubMedCrossRefGoogle Scholar
  45. 45.
    Alexander GE, DeLong MR, Strick PL. Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Ann Rev Neurosci 1986; 9: 357–81PubMedCrossRefGoogle Scholar
  46. 46.
    Alexander GE, Crutcher MD. Functional architecture of basal ganglia circuits: neural substrates of parallel processing. Trends Neurosci 1990; 13: 266–71PubMedCrossRefGoogle Scholar
  47. 47.
    Mendez MF, Adams NL, Lewandowski KS. Neurobehavioral changes associated with caudate lesions. Neurology 1989; 39: 349–54PubMedCrossRefGoogle Scholar
  48. 48.
    Strub RL. Frontal lobe syndrome in a patient with bilateral globus pallidus lesions. Arch Neurol 1989; 46: 1024–7PubMedCrossRefGoogle Scholar
  49. 49.
    Sandson TA, Daffner KR, Carvalho PA, et al. Frontal lobe dysfunction following infarction of the left-sided medial thalamus. Arch Neurol 1991; 48: 1300–3PubMedCrossRefGoogle Scholar
  50. 50.
    Stuss DT, Guberman A, Nelson R, et al. The neuropsychology of paramedian thalamic infarction. Brain Cogn 1988; 8: 348–78PubMedCrossRefGoogle Scholar
  51. 51.
    Cummings JL. Frontal-subcortical circuits and human behavior. Arch Neurol 1993; 50: 873–80PubMedCrossRefGoogle Scholar
  52. 52.
    Cummings JL. Anatomic and behavioral aspects of frontal-subcortical circuits. Ann N Y Acad Sci U S A 1995; 769: 1–13CrossRefGoogle Scholar
  53. 53.
    Milner B. Effects of different brain lesions on card sorting. Arch Neurol 1963; 9: 90–100CrossRefGoogle Scholar
  54. 54.
    Karnath HO, Wallesch CV. Inflexibility of mental planning: a characteristic disorder with prefrontal lesions. Neuropsy-chologia 1992; 30: 1011–6CrossRefGoogle Scholar
  55. 55.
    Grafman J, Holyoak K, Boller F. Structure and functions of the human prefrontal cortex. Vol 769. New York (NY): New York Academy of Sciences, 1995Google Scholar
  56. 56.
    Benecke R, Rothwell JC, Dick JPR, et al. Disturbance of sequential movements in patients with Parkinson’s disease. Brain 1987; 110: 361–79PubMedCrossRefGoogle Scholar
  57. 57.
    Roy E, Saint-Cyr JA, Taylor AE, et al. Movement sequencing disorder in Parkinson’s disease. Intl J Neurosci 1993; 73: 185–94Google Scholar
  58. 58.
    Taylor AE, Saint-Cyr JA, Lang AE. Frontal lobe dysfunction in Parkinson’s disease: the cortical focus of neostriatal outflow. Brain 1986; 109: 845–83PubMedCrossRefGoogle Scholar
  59. 59.
    Saint-Cyr JA, Taylor AE, Lang AE. Procedural learning and neostriatal dysfunction in man. Brain 1988; 111: 941–59PubMedCrossRefGoogle Scholar
  60. 60.
    Canavan AGM, Passingham RE, Marsden CD, et al. The performances on learning tasks of patients in the early stages of Parkinson’s disease. Neuropsychologia 1989; 27: 141–56PubMedCrossRefGoogle Scholar
  61. 61.
    Taylor AE, Saint-Cyr JA, Lang AE. Memory and learning in early Parkinson’s disease: evidence for a frontal lobe syndrome. Brain Cogn 1990; 2: 211–38CrossRefGoogle Scholar
  62. 62.
    Elsinger PJ, Grattan LM. Frontal lobe and frontal-striatal substrates for different forms of human cognitive flexibility. Neu-ropsychologia 1993; 31: 17–28Google Scholar
  63. 63.
    Pillon B, Dubois B, Cusimano G, et al. Does cognitive impairment in Parkinson’s disease result from non-dopaminergic lesions? J Neurol Neurosurg Psychiatry 1989; 52: 201–6PubMedCrossRefGoogle Scholar
  64. 64.
    Sagar HJ, Sullivan EV, Gabrieli JDE, et al. Temporal ordering and short-term memory deficits in Parkinson’s disease. Brain 1988; 111: 525–39PubMedCrossRefGoogle Scholar
  65. 65.
    Venneri A, Nicheli P, Modonesi G, et al. Impairment in dating and retrieving remote events in patients with early Parkinson’s disease. J Neurol Neurosurg Psychiatry 1997; 62: 410–3PubMedCrossRefGoogle Scholar
  66. 66.
    Partiot A, Vérin M, Pillon B, et al. Delayed response tasks in basal ganglia lesions in man: further evidence for a striato-frontal cooperation in behavioural adaptation. Neuropsychologia 1996; 34: 709–21PubMedCrossRefGoogle Scholar
  67. 67.
    Postle BR, Jonides J, Smith EE, et al. Spatial, but not object, delayed response is impaired in early Parkinson’s disease. Neuropsychology 1997; 11: 171–9PubMedCrossRefGoogle Scholar
  68. 68.
    Ferraro FR, Balota DA, Connor LT. Implicit memory and the formation of new associations in non-demented Parkinson’s disease individuals with senile dementia of the Alzheimer type: a serial reaction time (SRT) investigation. Brain Cogn 1993; 21: 163–80PubMedCrossRefGoogle Scholar
  69. 69.
    Jackson GM, Jackson SR, Harrison J, et al. Serial reaction time learning and Parkinson’s disease: evidence for a procedural learning deficit. Neuropsychologia 1995; 33: 577–93PubMedCrossRefGoogle Scholar
  70. 70.
    Ogden JA, Growden JH, Corkin S. Deficits on visuospatial tests involving forward planning in high-functioning parkinsonians. Neuropsychiat Neuropsych Behav Neurol 1990; 3: 125–39Google Scholar
  71. 71.
    Levin BE, Tomer R, Rey G. Cognitive impairments in Parkinson’s disease. Neurol Clin 1992; 10: 471–85PubMedGoogle Scholar
  72. 72.
    Pillon B, Deweer B, Agid Y, et al. Explicit memory in Alzheimer’s, Huntington’s and Parkinson’s disease. Arch Neurol 1993; 50: 374–9PubMedCrossRefGoogle Scholar
  73. 73.
    Taylor AE, Saint-Cyr JA. Executive function. In: Huber SJ, Cummings JL, editors. Parkinson’s disease: neurobehavioral aspects. New York (NY): Oxford University Press, 1992: 74–85Google Scholar
  74. 74.
    Playford DE, Jenkins IH, Passingham RF, et al. Impaired mesial frontal and putamen activation in Parkinson’s disease: a positron emission tomography study. Ann Neurol 1992; 3: 114–20Google Scholar
  75. 75.
    Peppard RF, Martin WRW, Carr GD, et al. Cerebral glucose metabolism in Parkinson’s disease with and without dementia. Arch Neurol 1992; 49: 1262–8PubMedCrossRefGoogle Scholar
  76. 76.
    Jagust WJ, Reed BR, Martin EM, et al. Cognitive function and regional cerebral blood flow in Parkinson’s disease. Brain 1992; 115: 521–37PubMedCrossRefGoogle Scholar
  77. 77.
    Brooks DJ. Functional imaging in relation to parkinsonian syndromes. J Neurol Sci 1993; 115: 1–17PubMedCrossRefGoogle Scholar
  78. 78.
    Ring HA, Bench CJ, Trimble MR, et al. Depression in Parkinson’s disease: a positron emission study. Br J Psychiatry 1994; 165: 333–9PubMedCrossRefGoogle Scholar
  79. 79.
    Eidelberg D, Moeller JR, Dhawan V, et al. The metabolic topography of parkinsonism. J Cereb Blood Flow Metab 1994; 14: 783–801PubMedCrossRefGoogle Scholar
  80. 80.
    Turjanski N, Brooks DJ. PET and the investigation of dementia in the parkinsonian patient. J Neural Transm 1997; Suppl. 51: 37–48Google Scholar
  81. 81.
    Owen AM, Doyon J, Dagher A, et al. Abnormal basal ganglia outflow in Parkinson’s disease identified with PET: implications for higher cortical functions. Brain 1998; 121: 949–65PubMedCrossRefGoogle Scholar
  82. 82.
    Bernheimer H, Birkmayer W, Hornykiewicz O, et al. Brain dopamine and the syndromes of Parkinson and Huntington. J Neurol Sci 1973; 20: 415–55PubMedCrossRefGoogle Scholar
  83. 83.
    Gibb WRG, Lees AJ. The significance of the Lewy body in the diagnosis of idiopathic Parkinson’s disease. Neuropathol Appl Neurobiol 1989; 15: 27–44PubMedCrossRefGoogle Scholar
  84. 84.
    Hornykiewicz O, Kish SJ. Biochemical pathophysiology of Parkinson’s disease. Adv Neurol 1986; 45: 19–34Google Scholar
  85. 85.
    Hirsch E, Graybiel AM, Agid YA. Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson’s disease. Nature 1988; 334: 345–8PubMedCrossRefGoogle Scholar
  86. 86.
    Kish SJ, Shannak K, Hornykiewicz O. Uneven pattern of dopa-mine loss in the striatum of patients with idiopathic Parkinson’s disease. N Engl J Med 1988; 318: 876–80PubMedCrossRefGoogle Scholar
  87. 87.
    Murray AM, Weihmueller FB, Marshall JF, et al. Damage to dopamine systems differs between Parkinson’s disease and Alzheimer’s disease with parkinsonism. Ann Neurol 1995; 37: 300–12PubMedCrossRefGoogle Scholar
  88. 88.
    Chinaglia G, Alvarez FJ, Probst A, et al. Mesostriatal and mesolimbic dopamine uptake binding sites are reduced in Parkinson’s disease and progressive supranuclear palsy: a quantitative autoradiographic study using [3H]mazindol. Neuroscience 1992; 49: 317–27PubMedCrossRefGoogle Scholar
  89. 89.
    Joyce JN. Differential response of striatal dopamine receptor subtypes and cholinergic muscarinic receptors to the loss of dopamine: III. Effects in Parkinson’s disease. Brain Res 1993; 600: 156–60PubMedCrossRefGoogle Scholar
  90. 90.
    Fearnley JM, Lees AJ. Aging and Parkinson’s disease: substantia nigra regional selectivity. Brain 1991; 114: 2283–301PubMedCrossRefGoogle Scholar
  91. 91.
    Javoy-Agid F, Agid Y. Is the mesocortical dopaminergic system involved in Parkinson’s disease? Neurology 1980; 30: 1326–30PubMedCrossRefGoogle Scholar
  92. 92.
    Rolls ET. The brain and emotion. Oxford: Oxford University Press, 1999Google Scholar
  93. 93.
    DeLong MR. Primate models of movement disorder of basal ganglia origin. Trends Neurosci 1990; 13: 281–5PubMedCrossRefGoogle Scholar
  94. 94.
    Besson MJ, Graybiel AM, Quinn B. Coexpression of neuropeptides in the cat’s striatum: an immunohistochemical study of substance P, dynorphin B and enkephalin. Neuroscience 1990; 39: 33–58PubMedCrossRefGoogle Scholar
  95. 95.
    Flaherty AW, Graybiel AM. Anatomy of the basal ganglia. In: Marsden CD, Fahn S, editors. Movement disorders 3. Boston (MA): Butterworth, 1994: 3–27Google Scholar
  96. 96.
    Rosvold HE. The frontal lobe system: cortical-subcortical interrelationships. Acta Neurobiol Exp (Warsz) 1972; 32: 439–60Google Scholar
  97. 97.
    Scatton B, Javoy-Agid F, Rouquier L, et al. Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson’s disease. Brain Res 1983; 275: 321–8PubMedCrossRefGoogle Scholar
  98. 98.
    Burns RS, Chiueh CC, Markey SP, et al. A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc Natl Acad Sci U S A 1983; 80: 4546–50PubMedCrossRefGoogle Scholar
  99. 99.
    Stern Y, Langston JW. Intellectual changes in patients with MPTP-induced parkinsonism. Neurology 1985; 35: 1506–9PubMedCrossRefGoogle Scholar
  100. 100.
    Zweig RM, Cardillo JE, Cohen M, et al. The locus ceruleus and dementia in Parkinson’s disese. Neurology 1993; 43: 986–91PubMedCrossRefGoogle Scholar
  101. 101.
    Agid Y, Graybiel AM, Ruberg M, et al. The efficacy of levodopa treatment declines in the course of Parkinson’s disease: do non-dopaminergic lesions play a role? Adv Neurol 1990; 53: 83–100PubMedGoogle Scholar
  102. 102.
    Gaspar P, Duyckaerts C, Alvarez C, et al. Alterations of dopaminergic and noradrenergic innervations in motor cortex in Parkinson’s disease. Ann Neurol 1991; 30: 365–74PubMedCrossRefGoogle Scholar
  103. 103.
    Marie RM, Barre L, Rioux P, et al. PET imaging of neocortical monoaminergic terminals in Parkinson’s disease. J Neural Transm 1995; 9: 55–71CrossRefGoogle Scholar
  104. 104.
    Sawaguchi T, Goldman-Rakic PS. D1 dopamine receptors in prefrontal cortex: involvement in working memory. Science 1991; 251: 247–50CrossRefGoogle Scholar
  105. 105.
    Pillon B, Michon A, Malapani C, et al. Are explicit memory disorders of progressive supranuclear palsy related to damage to striatofrontal circuits? Comparison with Alzheimer’s, Parkinson’s and Huntington’s disease. Neurology 1994; 44: 1264–70PubMedCrossRefGoogle Scholar
  106. 106.
    Iversen SD. Interactions between excitatory amino acids and dopamine systems in the forebrain: implications for schizophrenia and Parkinson’s disease. Behav Pharmacol 1995; 6: 478–91PubMedGoogle Scholar
  107. 107.
    Gsell W, Strein I, Krause U, et al. Neurochemical abnormalities in Alzheimer’s disease and Parkinson’s disease: a comparative review. J Neural Transm 1997; 151: 145–59CrossRefGoogle Scholar
  108. 108.
    Dubois B, Pillon B. Do cognitive changes of Parkinson’s disease result from dopamine depletion? J Neural Transm 1995; 45: 27–34Google Scholar
  109. 109.
    Goldman-Rakic PS. The cortical dopamine system: role in memory and cognition. Adv Pharmacol 1998: 42: 707–11PubMedCrossRefGoogle Scholar
  110. 110.
    Leenders KL, Brown R, Salmon E, et al. The relationship between ‘frontal’ function in patients with Parkinson’s disease and brain dopaminergic activity as measured by PET [abstract]. Neurology 1990; 40Suppl. 1: 168Google Scholar
  111. 111.
    Goldman-Rakic PS. Neurobiology: space and time in the mental universe. Nature 1997; 386: 559–60PubMedCrossRefGoogle Scholar
  112. 112.
    Cohen JD, Perlstein WM, Braver TS, et al. Temporal dynamics of brain activation during a working memory task. Nature 1997; 386: 604–7PubMedCrossRefGoogle Scholar
  113. 113.
    Owen AM. The functional organization of working memory processes within human lateral frontal cortex: the contribution of functional neuroimaging. Eur J Neurosci 1997; 9: 1329–39PubMedCrossRefGoogle Scholar
  114. 114.
    Brozoski T, Brown RM, Rosvold HE, et al. Cognitive deficit caused by regional depletion of dopamine in prefrontal cortex of Rhesus monkey. Science 1979; 205: 929–31PubMedCrossRefGoogle Scholar
  115. 115.
    Simon H. Dopaminergic A10 neurons and the frontal system. J Physiol 1981; 77: 81–95Google Scholar
  116. 116.
    Bubser M, Schmidt W. 6-OHDA lesions of the rat prefrontal cortex increases locomotor acticvity, impairs acquisition of delayed alternation tasks, but does not affect uninterrupted tasks in the radial maze. Behav Brain Res 1990; 37: 157–68PubMedCrossRefGoogle Scholar
  117. 117.
    Seamans JK, Floresco SB, Phillips AG. Selective impairment on a delayed radial arm task following local administration of a D1 but not a D2 antagonist into the prefrontal cortex [abstract]. Soc Neurosci Abst 1995; 21: 1942Google Scholar
  118. 118.
    Williams GV, Goldman-Rakic PS. Blockade of dopamine D1 receptors enhances memory fields of prefrontal neurons in primate cerebral cortex. Nature 1995; 376: 572–5PubMedCrossRefGoogle Scholar
  119. 119.
    Murphy BL, Arnsten AFT, Goldman-Rakic PS, et al. Increased dopamine turnover in the prefrontal cortex impairs spatial working memory perfromance in rats and monkeys. Proc Natl Acad Sci US A 1996; 93: 1325–9CrossRefGoogle Scholar
  120. 120.
    Zahrt J, Taylor JR, Mathew R, et al. Supranormal stimulation of D1 dopamine receptors in the rodent prefrontal cortex impairs spatial working memory performance. J Neurosci 1997; 17: 8528–5PubMedGoogle Scholar
  121. 121.
    Arnsten AFT, Goldman-Rakic PS. Noise stress impairs prefrontal cortical cognitive function in monkeys: evidence for a hyperdopaminergic mechanism. Arch Gen Psychiatry 1998; 55: 362–8PubMedCrossRefGoogle Scholar
  122. 122.
    Desimone R. Is dopamine a missing link? Nature 1995; 376: 549–50PubMedCrossRefGoogle Scholar
  123. 123.
    Funahashi S, Kubota K. Working memory and prefrontal cortex. Neurosci Res 1994; 21: 1–11PubMedCrossRefGoogle Scholar
  124. 124.
    Fuster JM. Memory in the cerebral cortex: an empirical approach to neural networks in the human brain and nonhuman primate. Cambridge (MA): Massachusetts Institute of Technology, 1995Google Scholar
  125. 125.
    Goldman-Rakic PS. Regional and cellular fractionation of working memory. Proc Natl Acad Sci U S A; 1996; 93: 13473–80PubMedCrossRefGoogle Scholar
  126. 126.
    Goldman-Rakic PS, Brown RM. Regional changes of monoamines in cerebral cortex and subcortical structures of aging rhesus monkeys. Neuroscience 1981; 6: 177–87PubMedCrossRefGoogle Scholar
  127. 127.
    Wenk GL, Pierce DJ, Struble RG, et al. Age-related changes in multiple neurotransmitter systems in the monkey brain. Neu-robiol Aging 1989; 10: 11–9CrossRefGoogle Scholar
  128. 128.
    Lidow MS, Goldman-Rakic PS, Gallager DW, et al. Distribution of dopaminergic receptors in the primate cerebral cortex: quantitative autoradiographyc analysis using (H3) raclopride, (H3) spiperone and (H3) SCH23390. Neuroscience 1991; 40: 657–71PubMedCrossRefGoogle Scholar
  129. 129.
    Arnsten AFT, Cai JX, Steere JC, et al. Dopamine D2 receptor mechanisms contribute to age-related cognitive decline: the effects of quinpirole on memory and motor performance in monkeys. J Neurosc 1995; 15: 3429–39Google Scholar
  130. 130.
    Fuxe K, Agnati LF, Kohler C, et al. Characterization of normal and supersensitive dopamine receptors: effects of ergot drugs and neuropeptides. J Neural Transm 1981; 51: 3–37PubMedCrossRefGoogle Scholar
  131. 131.
    Luciana M, Depue RA, Arbisis P, et al. Facilitation of working memory in humans by a D2 receptor agonist. J Cognit Neu-rosci 1992; 4: 58–68CrossRefGoogle Scholar
  132. 132.
    Luciana M, Collins PF. Dopaminergic modulation of working memory for spatial but not object cues in normal humans. J Cognit Neurosci 1997; 9: 330–47CrossRefGoogle Scholar
  133. 133.
    Kimberg DY, D’Esposito M, Farah MJ. Effects of bromocriptine on human subjects depend on working memory capacity. Neuro Report 1997; 8: 3581–5Google Scholar
  134. 134.
    Müller U, von Cranon DY, Pollmann S. D1-versus D2-receptor modulation of visuospatial working memory in humans. J Neurosci 1998; 18: 2720–8PubMedGoogle Scholar
  135. 135.
    Cooper JA, Sagar HJ, Tidswell P, et al. Slowed central processing in simple and go/no-go reaction time tasks in Parkinson’s disease. Brain 1994; 117: 517–29PubMedCrossRefGoogle Scholar
  136. 136.
    Bloxham CA, Dick DJ, Moore M. Reaction times and attention in Parkinson’s disease. J Neurol Neurosurg Psychiatry 1987; 50: 1178–83PubMedCrossRefGoogle Scholar
  137. 137.
    Owen AM, Beksinska M, James M, et al. Dopamine dependent spatial working memory deficits in Parkinson’s disease [abstract]. Soc Neurosc Abstr 1991; 17: 261Google Scholar
  138. 138.
    Owen AM, James M, Leigh PN, et al. Fronto-striatal cognitive deficits at different stages of Parkinson’s disease. Brain 1992; 115: 1727–51PubMedCrossRefGoogle Scholar
  139. 139.
    Lange KW, Robbins TW, Marsden CD, et al. L-Dopa withdrawal in Parkinson’s disease selectively impairs cognitive performance in tests sensitive to frontal lobe dysfunction. Psychopharmacology (Berl) 1992; 107: 394–404CrossRefGoogle Scholar
  140. 140.
    Cooper JA, Sagar HJ, Doherty SM, et al. Different effects of dopaminergic and anticholinergic therapies on cognitive and motor function in Parkinson’s disease. Brain 1992; 115: 1701–25PubMedCrossRefGoogle Scholar
  141. 141.
    Growdon JH, Kieburtz K, McDermott MP, et al. Levodopa improves motor function without impairing cognition in mild non-demented Parkinson’s disease patients. Neurology 1998; 50: 1327–31PubMedCrossRefGoogle Scholar
  142. 142.
    Gotham AM, Brown RG, Marsden CD. ‘Frontal’ cognitive function in patients with Parkinson’s disease ‘on’ and ‘off’ levodopa. Brain 1988; 111: 299–321PubMedCrossRefGoogle Scholar
  143. 143.
    Pillon B, Dubois B, Bonnet A-M, et al. Cognitive slowing in Parkinson’s disease fails to respond to levodopa treatment: the 15 objects test. Neurology 1989; 39: 762–8PubMedCrossRefGoogle Scholar
  144. 144.
    Meier MJ, Martin WE. Intellectual changes associated with levodopa therapy. JAMA 1970; 213: 465–6PubMedCrossRefGoogle Scholar
  145. 145.
    Arbit J, Boshes B, Blonsky R. Behavior and mentation changes during therapy. In: Barbeau A, McDowell FH, editors. L-dopa and parkinsonism. Philadelphia (PA): FA Davis, 1970: 329–35Google Scholar
  146. 146.
    Halgin R, Riklan M, Misiak H. Levodopa, parkinsonism and recent memory. J Nerv Ment Dis 1977; 164: 268–72PubMedCrossRefGoogle Scholar
  147. 147.
    Rogers D, Lees AJ, Smith E, et al. Bradyphrenia in Parkinson’s disease and psychomotor retardation in depressive illness: an experimental study. Brain 1987; 110: 761–76PubMedCrossRefGoogle Scholar
  148. 148.
    Mohr E, Fabbrini G, Ruggieri S, et al. Cognitive concomitants of dopamine system stimulation in Parkinsonian patients. J Neurol Neurosurg Psychiatry 1987; 50: 1192–6PubMedCrossRefGoogle Scholar
  149. 149.
    Huber SJ, Schulman HG, Paulson GW. Dose-dependent memory impairment in Parkinson’s disease. Neurology 1989; 39: 438–40PubMedCrossRefGoogle Scholar
  150. 150.
    Poewe W, Berger W, Benke TH, et al. High-speed memory scanning in Parkinson’s disease: adverse effects of levodopa. Ann Neurol 1991; 29: 670–3PubMedCrossRefGoogle Scholar
  151. 151.
    Rafal RD, Posner MI, Walker JA, et al. Cognition and the basal ganglia: separating mental and motor components of performance in Parkinson’s disease. Brain 1984; 107: 1083–94PubMedCrossRefGoogle Scholar
  152. 152.
    Lange KW, Paul GM, Robbins TW, et al. L-Dopa and frontal cognitive function in Parkinson’s disease. Adv Neurol 1993; 60: 475–8PubMedGoogle Scholar
  153. 153.
    Riklan M, Whelihan W, Cullinan T. Levodopa and psychomet-ric test performance in parkinsonism: 5 years later. Neurology 1976; 26: 173–9PubMedCrossRefGoogle Scholar
  154. 154.
    Portin R, Rinne UK. Neuropsychological responses of parkinsonian patients to long-term levodopa treatment. In: Rinne UK, Klinger M, Stamm G, editors. Parkinson’s disease: current progress, problems and management. Amsterdam: Elsevier North-Holland, 1980: 271–304Google Scholar
  155. 155.
    Melamed E, Hefti F, Pettibone DJ, et al. Aromatic L-amino acid decarboxylase in rat corpus striatum: implications for action of L-dopa in parkinsonism. Neurology 1981; 31: 651–5PubMedCrossRefGoogle Scholar
  156. 156.
    Zhang WQ, Tilson HA, Nanry KP, et al. Increased dopamine release from striata of rats after unilateral nigrostriatal bundle damage. Brain Res 1988; 461: 335–42PubMedCrossRefGoogle Scholar
  157. 157.
    Nutt JG, Holford HG. The response to levodopa in Parkinson’s disease: imposing pharmacological law and order. Ann Neu-rol 1996; 39: 561–73Google Scholar
  158. 158.
    Hughes AJ, Frankel JP, Kempster PA, et al. Motor response to levodopa in patients with parkinsonian motor fluctuations: a follow-up study over three years. J Neurol Neurosurg Psychiatry 1994; 57: 430–4PubMedCrossRefGoogle Scholar
  159. 159.
    Contin M, Riva R, Martinelli P, et al. Longitudinal monitoring of the levodopa concentration-effect relationship in Parkinson’s disease. Neurology 1994; 44: 1287–92PubMedCrossRefGoogle Scholar
  160. 160.
    Fabbrini G, Mouradian MM, Juncos JL, et al. Motor fluctuations in Parkinson’s disease: central pathophysiological mechanisms, Part I. Ann Neurol 1988; 24: 366–71PubMedCrossRefGoogle Scholar
  161. 161.
    Mouradian MM, Juncos JL, Fabbrini G, et al. Motor fluctuations in Parkinson’s disease: pathogenetic and therapeutic studies. Ann Neurol 1987; 22: 475–9PubMedCrossRefGoogle Scholar
  162. 162.
    Engber TM, Susel Z, Juncos JL, et al. Continuous and intermit-tent levodopa differentially affect rotation induced by D-1 and D-2 dopamine agonists. Eur J Pharmacol 1989; 168: 291–8PubMedCrossRefGoogle Scholar
  163. 163.
    Chase TN, Mouradian MM, Engber TM. Motor response complications and the function of striatal efferent systems. Neurology 1993; 43(6 Suppl.): 23–7Google Scholar
  164. 164.
    Albercrombie ED, Bonatz AE, Zigmond MJ. Effects of L-dopa on extracellular dopamine in striatum of normal and 6-hydroxydopamine-treated rats. Brain Research 1990; 525: 36–44CrossRefGoogle Scholar
  165. 165.
    Van Horne C, Hoffer BJ, Strömberg I, et al. Clearance and diffusion of locally applied dopamine in normal and 6-hydroxy-dopamine-lesioned rat striatum J Pharmacol Exp Ther 1992; 263: 1285–92PubMedGoogle Scholar
  166. 166.
    Nutt JG. On-off phenomenon: relation to levodopa pharmacokinetics and pharmacodynamics. Ann Neurol 1987; 22: 535–40PubMedCrossRefGoogle Scholar
  167. 167.
    Weddell RA, Weiser R. A double-blind cross-over placebo controlled trial of the effects of bromocriptine on psychomotor function, cognition, and mood in de novo patients with Parkinsonös disease. Behavioural Pharmacol 1995; 6: 81–91CrossRefGoogle Scholar
  168. 168.
    Delumeau JC, Bentué-Ferrer D, Gandon JM, et al. Monoamine oxidase inhibitors, cognitive functions and neurodegenerative diseases. J Neural Transm 1994; Suppl. 41: 259–66Google Scholar
  169. 169.
    Girotti F, Carella F, Grassi MP, et al. Motor and cognitive performances of parkinsonian patients in the on and off phases of the disease. J Neurol Neurosurg Psychiatry 1986; 49: 657–60PubMedCrossRefGoogle Scholar
  170. 170.
    Schneider JS, Pope-Coleman A. Cognitive deficits precede motor deficits in a slowly progressing model of parkinsonism in the monkey. Neurodegeneration 1995; 4: 245–55PubMedCrossRefGoogle Scholar
  171. 171.
    Schneider JS, Van Velson M, Menzaghi F, et al. Effects of the nicotinic acetylcholine receptor agonist SIB-1508Y on object retrieval performance in MPTP-treated monkeys: comparison with levodopa treatment. Ann Neurol 1998; 43: 311–7PubMedCrossRefGoogle Scholar
  172. 172.
    Lees AJ. When did Ray Kennedy’s Parkinson’s begin? Mov Disord 1992; 7: 110–6PubMedCrossRefGoogle Scholar
  173. 173.
    Sass KJ, Buchanan CP, Westerveld M, et al. General cognitive ability following unilateral and bilateral fetal ventral mesencephalic tissue transplantation for treatment of Parkinson’s disease. Arch Neurol 1995; 52: 680–6PubMedCrossRefGoogle Scholar
  174. 174.
    Goldstein M, Lieberman A, Lew JY, et al. Interaction of per-golide with central dopamine receptors. Proc Natl Acad Sci U S A 1980; 77: 3725–8PubMedCrossRefGoogle Scholar
  175. 175.
    Kulisevsky J, López-Villegas D, García-Sánchez C, et al. A six-month study of pergolide and levodopa in de-novo Parkinson’s disease patients. Clinical Neuropharmacology 1998; 21: 358–62PubMedGoogle Scholar
  176. 176.
    Kulisevsky J, García-Sánchez C, López-Villegas D, et al. Chronic effects of dopaminergic replacement on cognitive function in Parkinson’s disease: a one-year follow-up study on untreated patients comparing levodopa and pergolide [abstract]. Neurology 1998; 50Suppl. 4: 277Google Scholar
  177. 177.
    López-Villegas D, Kulisevsky J, Deus J, et al. Neuropsychological alterations in patients with computed tomography-detected basal ganglia calcification. Arch Neurol 1996; 53: 251–6PubMedCrossRefGoogle Scholar
  178. 178.
    Kulisevsky J, García-Sánchez C, Berthier ML, et al. Chronic effects of dopaminergic replacement on cognitive function in Parkinson’s disease: a two-year follow-up study of previously untreated patients. Mov Disord. In pressGoogle Scholar
  179. 179.
    Brown RG, Marsden CD. Dual task performance and processing resources in normal subjects and patients with Parkinson’s disease. Brain 1991; 114: 215–31PubMedGoogle Scholar
  180. 180.
    Cooper JA, Sagar HJ. Incidental and intentional recall in Parkinson’s disease: an account based on diminished attentional resources. J Clin Exp Neuropsichol 1993; 15: 713–31CrossRefGoogle Scholar
  181. 181.
    Dalrymple-Alford JC, Kalders AS, Jones RD, et al. A central executive deficit in patients with Parkinson’s disease. J Neurol Neurosurg Psychiatry 1994; 57: 360–7PubMedCrossRefGoogle Scholar
  182. 182.
    Malapani C, Pillon B, Dubois B, et al. Impaired simultaneous cognitive task performance in Parkinson’s disease: a dopamine-related dysfunction. Neurology 1994; 44: 319–26PubMedCrossRefGoogle Scholar
  183. 183.
    Rogers RD, Sahakian BJ, Hodges JR, et al. Dissociating executive mechanisms of task control following frontal lobe damage and Parkinson’s disease. Brain 1998; 121: 815–42PubMedCrossRefGoogle Scholar
  184. 184.
    Wilson FA, Scalaidhe SPO, Goldman-Rakic PS. Dissociation of object and spatial processing domains in primate prefrontal cortex. Science 1993; 260: 1955–8PubMedCrossRefGoogle Scholar
  185. 185.
    Zappia M, Oliveri RL, Montesanti R, et al. Loss of long-dura-tion response to levodopa over time in PD: implications for wearing-off. Neurology 1999; 52: 763–7PubMedCrossRefGoogle Scholar
  186. 186.
    Bayles KA, Tomoeda CK, Wood JA, et al. Change in cognitive function in idiopathic Parkinson’s disease. Arch Neurol 1996; 53: 1140–6PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 2000

Authors and Affiliations

  1. 1.Movement Disorders Unit, Neurology Department, Sant Pau HospitalAutonomous University of BarcelonaBarcelonaSpain

Personalised recommendations